Patents Assigned to Abraxis BioScience, LLC
  • Patent number: 10973806
    Abstract: The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 13, 2021
    Assignee: Abraxis BioScience, LLC
    Inventor: Neil P. Desai
  • Patent number: 10900951
    Abstract: The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: January 26, 2021
    Assignee: Abraxis BioScience, LLC
    Inventors: Viktor Peykov, Willard Foss, Daniel W. Pierce, Neil P. Desai
  • Patent number: 10744110
    Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin), wherein the individual has diabetes, has four or more metastatic sites, and/or is at least about 70 years old.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: August 18, 2020
    Assignee: Abraxis BioScience, LLC
    Inventor: Neil P. Desai
  • Patent number: 10705070
    Abstract: The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: July 7, 2020
    Assignee: Abraxis BioScience, LLC
    Inventors: Viktor Peykov, Willard Foss, Daniel W. Pierce, Neil P. Desai
  • Patent number: 10682420
    Abstract: The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: June 16, 2020
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 10660965
    Abstract: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”).
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 26, 2020
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 10555912
    Abstract: Provided herein are use of polymeric excipients, specifically polyvinyl alcohols, optionally in conjunction with sugars, as cryoprotectants to prevent aggregation of PEG-containing particles. Also provided are PEG-containing particles comprising such polymeric excipients.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 11, 2020
    Assignee: Abraxis BioScience, LLC
    Inventors: Willard Foss, Rajesh Shinde
  • Patent number: 10527604
    Abstract: The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.
    Type: Grant
    Filed: March 5, 2016
    Date of Patent: January 7, 2020
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventors: Viktor Peykov, Willard Foss, Daniel W. Pierce, Neil P. Desai
  • Patent number: 10413531
    Abstract: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 17, 2019
    Assignee: Abraxis BioScience, LLC
    Inventor: Neil P. Desai
  • Patent number: 10328031
    Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 25, 2019
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Markus Renschler
  • Patent number: 10258565
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 16, 2019
    Assignees: ABRAXIS BIOSCIENCE, LLC, MERCATOR MEDSYSTEMS, INC.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 10206887
    Abstract: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 19, 2019
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Viktor Peykov, Patrick Soon-Shiong
  • Patent number: 10076501
    Abstract: Provided herein are use of polymeric excipients, specifically polyvinyl alcohols, optionally in conjunction with sugars, as cryoprotectants to prevent aggregation of PEG-containing particles. Also provided are PEG-containing particles comprising such polymeric excipients.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: September 18, 2018
    Assignee: Abraxis BioScience, LLC
    Inventors: Willard Foss, Rajesh Shinde
  • Patent number: 10053504
    Abstract: The invention provides compositions comprising SPARC binding ScFv and its use.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: August 21, 2018
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • Patent number: 9962373
    Abstract: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: Abraxis BioScience, LLC
    Inventor: Neil P. Desai
  • Publication number: 20180064679
    Abstract: The present invention provides methods and compositions for treating cancer with taxane-based therapy. The individuals may have a high level of glucocorticoid receptor (GR) and/or a high level of glucocorticoid (GC). The taxane may be combined with another agent that down-regulates GR.
    Type: Application
    Filed: March 4, 2016
    Publication date: March 8, 2018
    Applicant: Abraxis BioScience, LLC
    Inventors: Daniel W. PIERCE, Marianna ZAVODOVSKAYA, Jinhong FAN
  • Patent number: 9884013
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 6, 2018
    Assignees: Abraxis BioScience, LLC, Mercator MedSystems, Inc.
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 9855220
    Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: January 2, 2018
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. Desai, Markus Renschler
  • Patent number: 9820949
    Abstract: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 21, 2017
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 9724323
    Abstract: The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: August 8, 2017
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong